JPRN-UMIN000015545已完成未知
Efficacy and safety of omalizumab (anti-IgE monoclinal antibody) on oral immunotherapy for patients with cow's milk allergy (randomized control study) - Omalizumab on oral immunotherapy for patients with cow's milk allergy
The Mami Mizutani foundation Kansai Medical University0 个研究点目标入组 50 人开始时间: 2014年11月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6years-old 至 15years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)severe bronchial asthma 2)severe atopic dermatitis 3)acute severe illenes 4)Decision of ineligibility by a physician.
研究者
相似试验
已完成
不适用
Efficacy and safety of omalizumab, an anti-IgE monoclonal antibody, in patients with seasonal allergic rhinitis: a systematic review.seasonal allergic rhinitisJPRN-UMIN000040561Showa University School of Medicine2,270
尚未招募
不适用
sefulness and safety of Omalizumab (anti-IgE monoclonal antibody) on oral immunotherapy for patients with severe food allergyFood allergyJPRN-UMIN000008688Kansai Medical University40
进行中（未招募）
1 期
A trial to see if anti-IgE (an antibody) will improve severe eczema that has not been cured by other types of medicineSevere eczema in childrenMedDRA version: 19.0 Level: LLT Classification code 10003641 Term: Atopic eczema System Organ Class: 100000004858MedDRA version: 19.0 Level: LLT Classification code 10014189 Term: Eczema allergic atopic System Organ Class: 100000004858EUCTR2010-020841-29-GBKing`s College London62
进行中（未招募）
不适用
Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe AsthmaAllergic AsthmaNCT06771934Qianfoshan Hospital60
已完成
不适用
Clinical effects of treatment with omalizumab in patients with asthmaBronchial asthmaJPRN-UMIN000002765Atami Hospital International University of Health and Welfare40